Signaturefd LLC Purchases 153 Shares of Axon Enterprise, Inc $AXON

Signaturefd LLC boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 18.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 991 shares of the biotechnology company’s stock after purchasing an additional 153 shares during the quarter. Signaturefd LLC’s holdings in Axon Enterprise were worth $821,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AXON. Jennison Associates LLC raised its holdings in Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares during the last quarter. Nuveen LLC bought a new stake in Axon Enterprise during the 1st quarter worth about $264,796,000. Westfield Capital Management Co. LP increased its stake in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after acquiring an additional 212,931 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after acquiring an additional 185,571 shares during the period. Finally, Axiom Investors LLC DE bought a new position in Axon Enterprise during the 1st quarter worth approximately $93,088,000. 79.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of analyst reports. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a report on Tuesday, August 5th. Needham & Company LLC restated a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a report on Wednesday, September 24th. JPMorgan Chase & Co. boosted their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a report on Thursday, July 17th. Wolfe Research initiated coverage on shares of Axon Enterprise in a report on Monday, July 7th. They set an “outperform” rating for the company. Finally, Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Price Performance

NASDAQ AXON opened at $716.02 on Tuesday. The business has a 50 day simple moving average of $757.89 and a 200 day simple moving average of $704.87. Axon Enterprise, Inc has a 52-week low of $394.24 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The stock has a market cap of $56.21 billion, a price-to-earnings ratio of 176.80, a PEG ratio of 27.53 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same period in the prior year, the business earned $1.20 EPS. Axon Enterprise’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity

In other Axon Enterprise news, CFO Brittany Bagley sold 870 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $773.25, for a total transaction of $672,727.50. Following the completion of the transaction, the chief financial officer owned 113,022 shares of the company’s stock, valued at $87,394,261.50. This represents a 0.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, President Joshua Isner sold 15,919 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the transaction, the president directly owned 238,379 shares of the company’s stock, valued at approximately $177,892,712.54. This trade represents a 6.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,932 shares of company stock worth $34,408,816. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.